What is AdjuCor?
Founded in 2012, AdjuCor is pioneering a paradigm shift in cardiac care. Unlike traditional ventricular assist devices that often trigger adverse hemocompatibility issues due to direct blood contact, AdjuCor's technology is engineered to provide mechanical support while entirely bypassing blood-contact complications. This breakthrough approach positions the company at the forefront of bio-engineering, targeting a massive unmet need in the treatment of heart failure. By focusing on non-invasive, complication-free mechanical assistance, AdjuCor is effectively redefining the standard of care for patients requiring long-term cardiac support, moving beyond the limitations of existing pump-based technologies.
How much funding has AdjuCor raised?
AdjuCor has raised a total of $37.9M across 2 funding rounds:
Series A
$2.6M
Series B
$35.3M
Series A (2019): $2.6M, investors not publicly disclosed
Series B (2021): $35.3M led by MitrAssist and Maurizio Group
Key Investors in AdjuCor
MitrAssist
MitrAssist is a medical device firm specializing in minimally invasive treatments for Mitral Regurgitation, focusing on innovative valve-in-valve implants that improve patient outcomes.
Maurizio Group
An investment entity providing strategic capital to support the growth and development of high-potential medical technology ventures.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the advancement of innovative cardiovascular medical devices.
What's next for AdjuCor?
With the recent influx of capital, AdjuCor is well-positioned to accelerate its clinical development pipeline and navigate the rigorous regulatory pathways required for market entry. The company's strategic roadmap likely involves scaling its manufacturing capabilities and expanding clinical trials to validate the long-term efficacy of its blood-contact-free platform. As the firm transitions from a development-stage entity to a commercial-ready medical device manufacturer, the focus will remain on securing further clinical data and establishing partnerships with major healthcare providers. This major enterprise-level funding provides the necessary runway to finalize product iterations and prepare for a potential market launch that could fundamentally alter the landscape of heart failure management.
See full AdjuCor company page
